Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation the targeted nanobubbles mediated LND against hepatocellular carcinoma by sonodynamic therapy with RNA-Seq

ABSTRACT: Sonodynamic therapy is an important approach in the treatment of hepatocellular carcinoma. A novel targeted nanobubbles loaded with HMME and LND was structured as sensibilizer, characterized the properties, and studied therapeutic effect on hepatocellular carcinoma. Next-generation high throughput RNA sequencing (RNA-Seq) was performed to accurately analyze the differential expression of mRNAs and lncRNA targets in hepatocellular carcinoma after sonodynamic therapy.

ORGANISM(S): Homo sapiens

PROVIDER: GSE171857 | GEO | 2022/03/02

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Evaluation the targeted nanobubbles mediated LND against hepatocellular carcinoma by sonodynamic therapy with RNA-Seq

Project description:Evaluation the targeted nanobubbles mediated LND against hepatocellular carcinoma by sonodynamic therapy with RNA-Seq

| PRJNA721203 | ENA

Next-generation sequencing is useful for quantitative analysis of the transcriptome of HMME-RGD@C3F8 NBs under low-frequency ultrasound irradiation combined with Elesclomol-Cu treated and untreated HCC cells

Project description:Hepatocellular carcinoma has a hidden onset and is often found at an advanced stage clinically. Moreover, because it is insensitive to radiotherapy and chemotherapy, its treatment is often difficult. In this study, we constructed nanobubbles loaded with sonosensitizer HMME and tumor-targeting peptide RGD (HMME-RGD@C3F8 NBs) combined with cuproptosis inducer Elesclomol-Cu to achieve sonodynamic/cuproptosis combined therapy for hepatocellular carcinoma (HCC). Furthermore, to explore the mechanism of the enhanced anti-tumor efficacy of synergistic sonodynamic/cuproptosis therapy, RNA sequencing was performed.

2025-08-01 | GSE274917 | GEO

Evaluation of ATAD2 as a potential target in hepatocellular carcinoma

Project description:We evaluated differentially expressed genes (DEGs) between hepatocellular carcinoma cell lines (Hep3B, SNU449, and PLC/PRF/5) treated with ATAD2 siRNA or control using Affymetrix array data whether ATAD2 could be potential target in hepatocellular carcinoma.

2022-06-15 | GSE178243 | GEO

Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma []

Project description:Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma []

| PRJNA1063443 | ENA

Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma

Project description:Lefamulin targets ILF3 to overcome targeted therapy resistance in hepatocellular carcinoma

| PRJNA1063444 | ENA

Project description:Single cell sequencing after sonodynamic therapy

| PRJNA869679 | ENA

Feasibility of global microRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib

Project description:Tumor cells were microdissected from FFPE sections of hepatocellular carcinoma (HCC) samples. micro RNA expression were correlated to clinical outcome and sorafenib-therapy. miRNA was labeled with the Affymetrix FlashTag Biotin HSR RNA Labeling Kit 20 microdissected hepatocellular carcinoma samples with detailed clinical data

2014-07-29 | E-GEOD-56059 | biostudies-arrayexpress

TARGETed Therapy Drug MONITOring in DIGestive Oncology

Project description:Targeted therapy drug monitoring in digestive oncology: Dosage of plasma levels of various multikinase inhibitors (MKI) in patients treated for advanced digestive cancer (gastrointestinal stromal tumor (GIST), metastatic colorectal cancer (mCRC), hepatocellular carcinoma (HCC), gastroenteropancreatic neuroendocrine tumor (gepNET), or pancreatic neuroendocrine tumor (pNET)), with the aim of determine the optimal dose adapted for each patient, in the future.

| 2739807 | ecrin-mdr-crc

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma

Project description:The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma. DNAJB1-PRKACA-derived HLA class I and HLA class II ligands induce multifunctional cytotoxic CD8+ and T-helper 1 CD4+ T cells, and their cellular processing and presentation in DNAJB1-PRKACA expressing tumor cells is demonstrated by mass spectrometry-based immunopeptidome analysis. Single-cell RNA sequencing further identifies multiple T cell receptors from DNAJB1-PRKACA-specific T cells. Vaccination of a fibrolamellar hepatocellular carcinoma patient, suffering from recurrent short interval disease relapses, with DNAJB1-PRKACA-derived peptides under continued Poly (ADP-ribose) polymerase inhibitor therapy induces multifunctional CD4+ T cells, with an activated T-helper 1 phenotype and high T cell receptor clonality. Vaccine-induced DNAJB1-PRKACA-specific T cell responses persist over time and, in contrast to various previous treatments, are accompanied by durable relapse free survival of the patient for more than 21 months post vaccination. Our preclinical and clinical findings identify the DNAJB1-PRKACA protein as source for immunogenic neoepitopes and corresponding T cell receptors and provide efficacy in a single-patient study of T cell-based immunotherapy specifically targeting this oncogenic fusion.

2022-10-13 | PXD029882 | Pride

Cells silenced for SDHB expression and tumor phenotype

Project description:Effect of SDHB silencing using siRNA methodologies in the tumor phenotype; We used microarrays to detail the global programme of gene expression when SDHB is silenced. Experiment Overall Design: Human hepatocellular carcinoma cell line Hep3B was stably silenced with control or SDHB-specific siRNAs. <br><br>This experiment was re-loaded into ArrayExpress in November 2010 after manual curation.

2008-06-11 | E-GEOD-10289 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data